ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma

Cancer Research

Volumn 65, Issue 10, 2005, Pages 4320-4333

  Frank, Natasha Y ^a   Margaryan, Armen ^b   Huang, Ying ^c   Schatton, Tobias ^b   Waaga Gasser, Ana Maria ^d   Gasser, Martin ^d   Sayegh, Mohamed H ^b   Sadee, Wolfgang ^c   Frank, Markus H ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; ABC TRANSPORTER; ABC TRANSPORTER B5; AMSACRINE; ANTHRAPYRAZOLE DERIVATIVE; ANTINEOPLASTIC AGENT; APHIDICOLIN; APHIDICOLIN GLYCINATE; BISANTRENE; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CD133 ANTIGEN; CHLORAMBUCIL; CHLORMETHINE; CYTARABINE; DAUNORUBICIN; DAUNORUBICIN DERIVATIVE; DEOXYDOXORUBICIN; DIANHYDROGALACTITOL; DOPAN; DOXORUBICIN; DOXORUBICIN DERIVATIVE; ETOPOSIDE; FTORDOPAN; GEMCITABINE; GLYCOPROTEIN P; HEPSULFAM; HYDROXYUREA; IMPROSULFAN; MELPHALAN; MENOGARIL; MITOMYCIN; MITOXANTRONE; MOLECULAR MARKER; N,N DIBENZYLDAUNOMYCIN; OXANTHRAZOLE; PIPERAZINE DERIVATIVE; PIPERAZINE MUSTARD; PIPERAZINEDIONE; PIRAZOFURIN; PORFIROMYCIN; PYRAZOLE DERIVATIVE; SPIROMUSTINE; TENIPOSIDE; TEROXIRONE; THIOTEPA; TRETAMINE; UNCLASSIFIED DRUG; URAMUSTINE; ZORUBICIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL FUSION; CELL POLARITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; DRUG TRANSPORT; GENE EXPRESSION; HUMAN; HUMAN CELL; LD 50; MELANOMA; MEMBRANE POTENTIAL; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; STEM CELL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; MELANOMA; P-GLYCOPROTEIN; PEPTIDES; STEM CELLS;

EID: 20144364789     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3327     Document Type: Article

References (59)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
2. Gros P, Ben Neriah YB, Croop JM, Housman DE. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986;323:728-31.
3. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985;316:817-9.
4. Roninson IB, Chin JE, Choi KG, et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A 1986;83:4538-42.
5. Ueda K, Cornwell MM, Gottesman MM, et al. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 1986;141:956-62.
6. van Helvoort A, Smith AJ, Sprong H, et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996;87:507-17.
7. Bosch I, Dunussi-Joannopoulos K, Wu RL, Furlong ST, Croop J. Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein. Biochemistry 1997;36:5685-94.
8. Romsicki Y, Sharom FJ. Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter. Biochemistry 2001;40:6937-47.
9. Smit JJ, Schinkel AH, Oude Elferink RP, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993;75:451-62.
10. Raghu G, Park SW, Roninson IB, Mechetner EB. Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp Hematol 1996;24:1258-64.
11. Drach J, Gsur A, Hamilton G, et al. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (1L-2), IL-4, and interferon-γ in normal human T lymphocytes. Blood 1996;88:1747-54.
12. Frank MH, Denton MD, Alexander SI, Khoury SJ, Sayegh MH, Briscoe DM. Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J Immunol 2001;166:2451-9.
13. Pendse S, Sayegh MH, Frank MH. P-glycoprotein - a novel therapeutic target for immunomodulation in clinical transplantation and autoimmunity? Curr Drug Targets 2003;4:469-76.
14. Bunting KD, Galipeau J, Topham D, Benaim E, Sorrentino BP. Effects of retroviral-mediated MDR1 expression on hematopoietic stem cell self-renewal and differentiation in culture. Ann N Y Acad Sci 1999;872:125-40; discussion 140-121.
15. Randolph GJ, Beaulieu S, Lebecque S, Steinman RM, Muller WA. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 1998;282:480-3.
16. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000;25:1-6.
17. Gollapud S, Gupta S. Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival. J Clin Immunol 2001;21:420-30.
18. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.
19. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998;95:15665-70.
20. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998;58:5337-9.
21. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22:7468-85.
22. Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update. Melanoma Res 1999;9:51-8.
23. Helmbach H, Sinha P, Schadendorf D. Human melanoma: drug resistance. Recent Results Cancer Res 2003;161:93-110.
24. Li Y, McClay EF. Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 2002;29:413-26.
25. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-24.
26. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66.
27. Danson S, Lorigan P, Arance A, et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003;21:2551-7.
28. Bradbury PA, Middleton MR. DNA repair pathways in drug resistance in melanoma. Anticancer Drugs 2004;15:421-6.
29. Frank NY, Pendse SS, Lapchak PH, et al. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem 2003;278:47156-65.
30. Van der Bliek AM, Baas F, Ten Houte de Lange T, Kooiman PM, Van der Velde-Koerts T, Borst P. The human mdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively spliced mRNAs in liver. EMBO J 1987;6:3325-31.
31. Aleman C, Annereau JP, Liang XJ, et al. P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Res 2003;63:3084-91.
32. Frei E III, Holden SA, Gonin R, Waxman DJ, Teicher BA. Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies. Cancer Chemother Pharmacol 1993;33:113-22.
33. Alvarez M, Paull K, Monks A, et al. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest 1995;95:2205-14.
34. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44.
35. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24:227-35.
36. Grimley PM, Aszalos A. Early plasma membrane depolarization by α interferon: biologic correlation with antiproliferative signal. Biochem Biophys Res Commun 1987;146:300-6.
37. Weinstein JN, Kohn KW, Grever MR, et al. Neural computing in cancer drug development: predicting mechanism of action. Science 1992;258:447-51.
38. Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343-9.
39. Huang Y, Anderle P, Bussey KJ, et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004;64:4294-301.
40. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991;66:85-94.
41. Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7:1028-34.
42. Wulf GG, Wang RY, Kuehnle I, et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001;98:1166-73.
43. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-12.
44. Uchida N, Buck DW, He D, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 2000;97:14720-5.
45. Schwartz PH, Bryant PJ, Fuja TJ, Su H, O'Dowd DK, Klassen H. Isolation and characterization of neural progenitor cells from post-mortem human cortex. J Neurosci Res 2003;74:838-51.
46. Belicchi M, Pisati F, Lopa R, et al. Human skin-derived stem cells migrate throughout forebrain and differentiate into astrocytes after injection into adult mouse brain. J Neurosci Res 2004;77:475-86.
47. van Kempen LC, van den Oord JJ, van Muijen GN, Weidle UH, Bloemers HP, Swart GW. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 2000;156:769-74.
48. Etoh T, Byers HR, Mihm MC Jr. Integrin expression in malignant melanoma and their role in cell attachment and migration on extracellular matrix proteins. J Dermatol 1992;19:841-6.
49. v as prognostic factors in human metastatic melanoma. Melanoma Res 2004;14:29-37.
50. De Wit PE, Van Muijen GN, De Waal RM, Ruiter DJ. Pathology of malignant melanoma, including new markers and techniques in diagnosis and prognosis. Curr Opin Oncol 1996;8:143-51.
51. Ahrens T, Assmann V, Fieber C, et al. CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation. J Invest Dermatol 2001;116:93-101.
52. Altomonte M, Montagner R, Fonsatti E, et al. Expression and structural features of endoglin (CD105), a transforming growth factor β1 and β3 binding protein, in human melanoma. Br J Cancer 1996;74:1586-91.
53. Robinson LJ, Roepe PD. Effects of membrane potential versus pHi on the cellular retention of doxorubicin analyzed via a comparison between cystic fibrosis transmembrane conductance regulator (CFTR) and multidrug resistance (MDR) transfectants. Biochem Pharmacol 1996;52:1081-95.
54. Spalletti-Cernia D, D'Agnano I, Sorrentino R, et al. Verapamil reverts resistance to drug-induced apoptosis in Ki-ras-transformed cells by altering the cell membrane and the mitochondrial transmembrane potentials. Oncol Res 2002;13:25-35.
55. Pallis M, Turzanski J, Higashi Y, Russell N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 2002;43:1221-28.
56. Norwood K, Wang RY, Hirschmann-Jax C, et al. An in vivo propagated human acute myeloid leukemia expressing ABCA3. Leuk Res 2004;28:295-9.
57. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
58. Swart GW. Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol 2002;81:313-21.
59. Oswald J, Boxberger S, Jorgensen B, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004;22:377-84.